Biodexa Pharmaceuticals Stock Surges on Trial Progress

Biodexa Pharmaceuticals' stock increased by 45.88% following promising FDA designations and investor optimism as European sites become active for Phase 3 Serenta clinical trial. The company has enrolled three patients in Europe for its eRapa trial, marking progress in treatment options for familial adenomatous polyposis.